Ultragenyx Pharmaceutical (RARE) Operating Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has 7 years of Operating Leases data on file, last reported at $24.0 million in Q4 2025.

• Quarterly Operating Leases fell 20.0% year-over-year to $24.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.0 million (down 20.0% YoY) and the FY2025 annual result came in at $24.0 million, down 20.0% from the prior year.
• Operating Leases advanced to $24.0 million in Q4 2025 per RARE's latest filing, from $21.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $36.8 million in Q1 2021 and bottomed at $14.8 million in Q2 2023.
• The 5-year median for Operating Leases is $26.8 million (2022), against an average of $26.8 million.
• The widest annual swing landed in 2023, when Operating Leases tumbled 42.69%; it then surged 73.4% in 2024.
• Tracing RARE's Operating Leases over 5 years: stood at $30.9 million in 2021, then slumped by 35.89% to $19.8 million in 2022, then jumped by 54.31% to $30.6 million in 2023, then decreased by 1.88% to $30.0 million in 2024, then fell by 20.0% to $24.0 million in 2025.
• Per Business Quant, the three latest RARE Operating Leases figures stand at $24.0 million (Q4 2025), $21.7 million (Q3 2025), and $24.5 million (Q2 2025).

Peer Comparison